L'Oreal is making human skin in the lab to test products and reduce animal testing. Coming soon: 3-D printed skin for tissue engineering. » Read More
CNBC's Meg Tirrell reports on the biggest health issues and how industry leaders are thinking about the future of health care in America. David Gluckman, Lazard co-head of health care, weighs in. » Read More
By: Alexandra Ossola
Over the course of a year, scientists sampled the microbes in a newly-opened facility in Chicago, Vocativ reports. » Read More
CNBC's Meg Tirrell reports on Puma's stock spike after the FDA board votes in support of its breast cancer drug. » Read More
CNBC's Leslie Picker takes a look at Bill Ackman's stock-picking history, including winners and losers.
"Fast Money Halftime Report" trader Josh Brown weighs in on Valeant, as the stock plunges following Bill Ackman's decision to sell his entire stake.
CNBC's Meg Tirrell takes a closer look at President Trump's FDA pick Dr. Scott Gottlieb, and what this nomination means for the health care sector. With “Fast Money Halftime Report” traders.
The bill could overturn a nondiscrimination law known as GINA as well as the American Disabilities Act, STAT reports.
The best-performing large-cap ETF is enjoying an incredible comeback in 2017.
China's Shanghai Fosun Pharmaceutical is planning a bid for German generic drugmaker Stada.
Promising new research suggests that marijuana could be used to treat Alzheimer's, but there's a major roadblock: the federal government.
Biotech stocks might be in a slump, but there's an upside, one analyst says.
Michael Yee, RBC Capital Markets biotech analyst, weighs in on the biotech sector amid President Trump's drug pricing concerns and GOP healthcare proposal.
EpiPen's seller Mylan came under fire last summer for having increased the price of the auto-injector more than 500 percent.
Ava is an ovulation tracking bracelet that is worn at night when the woman is sleeping to track her most fertile days.
Ava is an ovulation tracking bracelet worn at night when the woman is sleeping to track her most fertile days.
South Korea's Samsung Bioepis has won a high-stakes court case against U.S. drug firm AbbVie.
The HPV vaccine is increasingly becoming the primary test for reducing cervical cancer deaths, STAT News reports.
Mylan was criticized last year after hiking EpiPen prices to $600, but has seen its stock surge after Donald Trump's election.
CNBC's Jim Cramer weighs in on Mylan and CEO Heather Bresch.
CNBC's Brian Sullivan asks Mylan CEO Heather Bresch about the company's outperformance relative to its peers.
Mylan CEO Heather Bresch discusses the company's progress from its EpiPen firestorm.
Plurimi Investment Managers CIO Patrick Armstrong weighs in on his investment strategy, adding that almost everything has been overpriced in the last two months.
The drug, known as JCAR015, was being tested in adults with relapsed acute lymphoblastic leukemia, a rare and deadly blood cancer.
Get the best of CNBC in your inbox